|
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review |
Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K, Sutton A
|
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K, Sutton A
. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technology Assessment 2012; 16(5): 1-202 Authors' objectives The objective of this research was to evaluate the clinical effectiveness and cost-effectiveness of pharmacological interventions compared with each other and with standard care in obese patients in primary care. Authors' conclusions Although orlistat, sibutramine and rimonabant are all effective at reducing weight and body mass index and, compared with placebo, are all cost-effective, both sibutramine and rimonabant have been withdrawn because of safety concerns relating to potential treatment-induced fatal adverse events. Indexing Status Subject indexing assigned by CRD MeSH Cost-Benefit Analysiss; Obesity; Overweight; Primary Health Care Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32010000307 Date abstract record published 21/04/2010 |
|
|
|